Clicky

Larimar Therapeutics, Inc.(LRMR)

Description: Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.


Keywords: Medicine Biotechnology Drug Discovery Rare Diseases Clinical Pharmacology Genetic Diseases Progressive Fusion Protein Ataxia Friedreich's Ataxia Trinucleotide Repeat Disorders

Home Page: www.larimartx.com

LRMR Technical Analysis

Three Bala Plaza East
Bala Cynwyd, PA 19004
United States
Phone: 844 511 9056


Officers

Name Title
Dr. Carole S. Ben-Maimon M.D. CEO, Pres & Director
Mr. Michael Celano CPA Sec. & CFO
Mr. John Berman VP of Fin. & Operations
Ms. Jennifer Spokes Johansson VP of Regulatory Affairs & Counsel
Dr. Nancy M. Ruiz Chief Medical Officer
Mr. Francis Michael Conway VP & Controller

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.6336
Price-to-Sales TTM: 0
IPO Date: 2014-06-19
Fiscal Year End: December
Full Time Employees: 31
Back to stocks